or Try an Advanced Search...

    Technical Analysis for AUTL - Autolus Therapeutics plc

    Grade Last Price % Change Price Change
    D 3.50 3.86% 0.13
    AUTL closed up 3.86 percent on Friday, November 1, 2024, on 1.98 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: Nov 12
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical AUTL trend table...
    Date Alert Name Type % Chg
    MACD Bearish Centerline Cross Bearish 0.00%
    Jack-in-the-Box Bearish Bearish Swing Setup 0.00%
    Calm After Storm Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Below Lower BB Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New Downtrend Bearish 3.86%
    Expansion Breakdown Bearish Swing Setup 3.86%
    Older End-of-Day Signals for AUTL ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 16 hours ago
    Possible Inside Day about 17 hours ago
    3x Volume Pace about 20 hours ago
    Up 5% about 20 hours ago
    2x Volume Pace about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    AUTL Chart by TradingView
    Basic chart:

    Profile

    Autolus Therapeutics Ltd is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and AUTO6.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Pharmacy Treatment Of Cancer

    Is AUTL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 28 Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
    Oct 17 Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy
    Oct 16 Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
    Oct 16 Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts
    Oct 9 Autolus Therapeutics PLC (AUTL) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
    Sep 24 Autolus Therapeutics reports 1H results
    Sep 19 Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
    Sep 12 Autolus Therapeutics PLC (AUTL): Fast-Growing Penny Stock To Consider
    Sep 6 Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case
    Sep 2 Autolus Therapeutics plc (AUTL): The Best Multibagger Penny Stock of 2025?
    See more AUTL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.45
    52 Week Low 3.0601
    Average Volume 960,873
    200-Day Moving Average 4.63
    50-Day Moving Average 4.02
    20-Day Moving Average 4.24
    10-Day Moving Average 4.21
    Average True Range 0.27
    RSI (14) 35.48
    ADX 34.64
    +DI 20.42
    -DI 31.99
    Chandelier Exit (Long, 3 ATRs) 4.18
    Chandelier Exit (Short, 3 ATRs) 4.15
    Upper Bollinger Bands 4.95
    Lower Bollinger Band 3.52
    Percent B (%b) -0.01
    BandWidth 33.79
    MACD Line -0.03
    MACD Signal Line 0.09
    MACD Histogram -0.1218
    Fundamentals Value
    Market Cap 608.96 Million
    Num Shares 174 Million
    EPS -0.98
    Price-to-Earnings (P/E) Ratio -3.57
    Price-to-Sales 200.99
    Price-to-Book 6.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.75
    Resistance 3 (R3) 3.74 3.65 3.71
    Resistance 2 (R2) 3.65 3.59 3.66 3.69
    Resistance 1 (R1) 3.58 3.55 3.62 3.58 3.68
    Pivot Point 3.49 3.49 3.51 3.49 3.49
    Support 1 (S1) 3.41 3.43 3.45 3.42 3.32
    Support 2 (S2) 3.32 3.39 3.33 3.31
    Support 3 (S3) 3.25 3.32 3.29
    Support 4 (S4) 3.25